Brief: Verve Therapeutics And Lilly Relationship Expands To Include Verve's In Vivo Gene Editing Programs Targeting PCSK9 And ANGPTL3

Beam Therapeutics

31/10/2023 10:33

Oct 31 (Reuters) - Eli Lilly and Co  LLY.N :
    * VERVE THERAPEUTICS INC: CO AND LILLY RELATIONSHIP EXPANDS
TO
INCLUDE VERVE'S IN VIVO GENE EDITING PROGRAMS TARGETING PCSK9
AND ANGPTL3
    * VERVE THERAPEUTICS INC: FOR PCSK9 AND ANGPTL3 PRODUCT
CANDIDATES, LILLY NOW HOLDS PRODUCT RIGHTS PREVIOUSLY HELD BY
BEAM
    * VERVE THERAPEUTICS INC: VERVE HOLDS ALL PRODUCT RIGHTS FOR
PCSK9
AND ANGPTL3 PROGRAMS OUTSIDE UNITED STATES
    * VERVE THERAPEUTICS INC: VERVE RETAINS CONTROL OF
DEVELOPMENT AND
COMMERCIALIZATION OF ALL COLLABORATION PRODUCTS

Source text for Eikon:  ID:nGNX2nV0xF 
Further company coverage:  LLY.N 

 ((Reuters.Briefs@thomsonreuters.com;))